Medical Weight Loss
Nurse-Led. Physician-Guided. Results-Driven.
The Science Behind the Results
GLP-1 receptor agonists — Semaglutide and Tirzepatide — are the same active compounds behind Ozempic, Wegovy, and Mounjaro. They work by mimicking a natural hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity. The result: sustained weight loss without the white-knuckle willpower.
Our program pairs these medications with physician oversight, Nurse Tina's hands-on guidance, and a complete support system — diet plans, workout plans, weekly check-ins, and a private community. This isn't a prescription and a prayer. It's a program.
Four Steps to a New You
Free Consultation
No cost, no pressure. We review your health history, goals, and whether GLP-1 therapy is the right fit for your body.
Nurse + Physician Consult
Nurse Tina coordinates with our supervising physician to evaluate your labs, confirm candidacy, and build your personalized protocol.
Weekly Injections
Your medication is administered weekly with dosage titration based on your response. We monitor everything — side effects, progress, adjustments.
Successful Outcome
Consistent weight loss, improved metabolic markers, and a body you actually feel good in. We don't stop until you're where you want to be.
Choose Your Program
Both programs include everything listed below. The only difference is the medication. 10% off your first visit — because starting should feel good.
+ $25 one-time consultation fee
- Same compound as Ozempic & Wegovy
- Weekly subcutaneous injections
- Physician-supervised dosing
- Full support package included
- HSA & FSA accepted
+ $25 one-time consultation fee
- Same compound as Mounjaro & Zepbound
- Dual GIP/GLP-1 receptor agonist
- Greater average weight loss in trials
- Full support package included
- HSA & FSA accepted
10% discount applied to your first visit. Mention "first drip" when booking.
What's Included in Every Program
The Numbers Speak
Your Titration Timeline
Phase 1 — Weeks 1–4
Starting dose to assess tolerance. Your body adjusts to the medication while we monitor for side effects and establish your baseline response.
Semaglutide: 0.25 mg | Tirzepatide: 2.5 mg
Phase 2 — Weeks 5–8
First dose increase. Appetite suppression becomes more noticeable. Most clients begin seeing consistent weight loss during this phase.
Semaglutide: 0.5 mg | Tirzepatide: 5 mg
Phase 3 — Weeks 9–12
Therapeutic dosing ramps up. Weight loss accelerates. We fine-tune your nutrition and exercise plan based on real progress data.
Semaglutide: 1.0 mg | Tirzepatide: 7.5 mg
Phase 4 — Weeks 13+
Maintenance or continued titration based on your goals. Some clients reach target weight here; others continue to higher doses under physician guidance.
Semaglutide: 1.7–2.4 mg | Tirzepatide: 10–15 mg
Eat Smarter, Not Less
GLP-1 medications reduce appetite — but what you eat still matters. We give you a clear, practical nutrition framework so every calorie counts toward your goal.
Common Questions
GLP-1 therapy is appropriate for adults with a BMI of 27 or higher (with at least one weight-related condition) or a BMI of 30+. Our physician evaluates your full health history during the consultation to confirm you're a fit. If you've struggled with traditional diets and exercise alone, this program was designed for you.
The most common side effects are mild nausea, decreased appetite (that's the point), and occasional digestive changes during the first few weeks. These typically resolve as your body adjusts and we titrate your dose. Serious side effects are rare but monitored closely by our physician throughout your program.
Most clients notice reduced appetite within the first week and visible weight loss within 4–6 weeks. Average loss is approximately 4 pounds per week once you reach therapeutic dosing. By week 12, many clients have lost 15–25+ pounds. Results vary based on starting weight, adherence to the nutrition plan, and individual metabolism.
Both are GLP-1 receptor agonists that reduce appetite and promote weight loss. Semaglutide (the compound in Ozempic and Wegovy) targets the GLP-1 receptor. Tirzepatide (the compound in Mounjaro and Zepbound) targets both GLP-1 and GIP receptors, which clinical trials have shown produces greater average weight loss. Our physician helps you choose based on your goals, health profile, and budget.
GLP-1 medications are not recommended for individuals with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or a history of pancreatitis. They're also not appropriate during pregnancy or breastfeeding. Our physician reviews your complete medical history before prescribing to ensure safety.
Ready for Your Transformation?
Your free consultation is one call away. No commitment, no pressure — just a conversation about what's possible.